Anti-C3 / C3b antibody [2B10B9B2] (ab106108)


  • Product name
    Anti-C3 / C3b antibody [2B10B9B2]
    See all C3 / C3b primary antibodies
  • Description
    Mouse monoclonal [2B10B9B2] to C3 / C3b
  • Host species
  • Specificity
    ab106108 reacts with an epitope on C3b. It reacts both with intact C3 and C3b.
  • Tested applications
    Suitable for: WB, ELISAmore details
    Unsuitable for: IP
  • Species reactivity
    Reacts with: Rat
  • Immunogen

    Rat C3/ C3b



Our Abpromise guarantee covers the use of ab106108 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/50. Predicted molecular weight: 187 kDa.
ELISA 1/50.
  • Application notes
    Is unsuitable for IP.
  • Target

    • Function
      C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.
      Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.
    • Tissue specificity
    • Involvement in disease
      Defects in C3 are the cause of complement component 3 deficiency (C3D) [MIM:613779]. A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis.
      Genetic variation in C3 is associated with susceptibility to age-related macular degeneration type 9 (ARMD9) [MIM:611378]. ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.
      Defects in C3 are a cause of susceptibility to hemolytic uremic syndrome atypical type 5 (AHUS5) [MIM:612925]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype.
    • Sequence similarities
      Contains 1 anaphylatoxin-like domain.
      Contains 1 NTR domain.
    • Post-translational
      C3b is rapidly split in two positions by factor I and a cofactor to form iC3b (inactivated C3b) and C3f which is released. Then iC3b is slowly cleaved (possibly by factor I) to form C3c (beta chain + alpha' chain fragment 1 + alpha' chain fragment 2), C3dg and C3f. Other proteases produce other fragments such as C3d or C3g.
      Phosphorylation sites are present in the extracelllular medium.
    • Cellular localization
    • Information by UniProt
    • Database links
    • Alternative names
      • Acylation-stimulating protein cleavage product antibody
      • AHUS5 antibody
      • ARMD9 antibody
      • ASP antibody
      • C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1 antibody
      • C3 antibody
      • CO3_HUMAN antibody
      • Complement C3 antibody
      • Complement C3 beta chain antibody
      • Complement C3c alpha' chain fragment 2 antibody
      • Complement component 3 antibody
      • Complement component C3 antibody
      • Complement factor 3 antibody
      • CPAMD1 antibody
      • Plp antibody
      see all


    ab106108 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    Thank you for contacting us.

    There are following antibodies that are best match as per your request. Please check the datasheets.

    ab11871, ab106108

    I hope this information is helpful to you. Please do not hesitate to contact ...

    Read More

    Thank you very much for your interest in ab106108.
    To our knowledge, ab106108 has not been tested in IF. Therefore, I can offer a discount off a future purchase if you buy ab106108 now, test it in IF and submit feedback to us in the form of an Abr...

    Read More


    Sign up